Kymab Receives $40 Million Investment From Gates Foundation and Wellcome Trust - - BioPharm International

ADVERTISEMENT

Kymab Receives $40 Million Investment From Gates Foundation and Wellcome Trust



Kymab, a monoclonal antibody biopharmaceutical company, has raised $40 million in a Series B financing. The Bill & Melinda Gates Foundation joins existing investor, the Wellcome Trust, each investing $20 million.

The funds will enable Kymab to increase the potential of its kymouse platform and advance its pipeline of therapeutic human monoclonal antibodies in areas of unmet medical need. Kymab will also collaborate with the Gates Foundation and its partners on vaccine antigen discovery R&D with a focus on malaria and HIV. Recent data published in Nature Biotechnology demonstrates that the kymouse technology yields an antibody library constituted from 100 trillion different antibodies, in which rare high-quality antibodies can be selected and developed into therapeutics.

In addition, Kymab will pursue a limited number of collaborations to identify and develop therapeutic antibodies in a range of diseases. Kymab has also developed Kymab Access, a program that enables academic researchers to pursue the discovery and development of novel human monoclonal antibody therapeutics and vaccines by partnering with Kymab and its kymouse antibody technology.

Source: Kymab

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Harnessing the Power of Modified T Cells to Treat Cancer
October 17, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Industry Stakeholders Tackle the Use of Biological Qualifiers at WHO Naming Session
October 16, 2014
Pfizer Ireland Plant Receives ISPE Award
October 16, 2014
Author Guidelines

Click here